Subscribe to RSS
DOI: 10.1055/a-2181-1018
Pathophysiologie der Sepsis
Die Sepsis ist noch immer eines der bedrohlichsten Krankheitsbilder der modernen Medizin mit einer hohen Mortalitätsrate. Das zunehmende Wissen um die Komplexität und Heterogenität der septischen Immunpathologie kann Wege eröffnen, zukünftig Sepsispatienten individueller – und somit erfolgreicher – behandeln zu können. Dieser Beitrag stellt den aktuellen Kenntnisstand der Pathophysiologie der Sepsis und des septischen Schocks dar.
-
Sepsis ist definiert als eine schwerwiegende dysregulierte Immunantwort auf dem Boden einer Infektion, aus der eine Endorganstörung resultiert.
-
Im Zentrum der septischen Pathophysiologie steht zu Beginn ein sog. Zytokinsturm, der maßgeblich durch die Antwort des angeborenen Immunsystems getragen wird. Im Verlauf kann sich eine eher immunparalytische Situation einstellen.
-
Exogene PAMPs und endogene DAMPs aktivieren sog. PRRs, welche mannigfaltige Downstream-Pathways aktivieren und die weitere Immunantwort bahnen.
-
Die Sepsis ist weder ein reines pro- noch antiinflammatorisches Krankheitsbild. Vielmehr laufen pro- und antiinflammatorische Prozesse stets parallel zueinander ab, sodass die immunologische Gesamtsituation je nach Ausprägungsgrad der einzelnen Komponenten patientenindividuell und zeitabhängig deutlich differiert.
-
Der septische Schock zeichnet sich durch eine kombinierte Störung sowohl der Makro- als auch der Mikrozirkulation aus. Die hieraus resultierenden Oxygenierungsstörungen bedingen die sepsisdefinierenden Endorganstörungen.
-
Das Wissen um die Heterogenität der septischen Immunpathologie muss bei der Konzeption zukünftiger Sepsisstudien sowie der Therapieplanung des individuellen Sepsispatienten Berücksichtigung finden. Das Ziel ist es, eine zunehmende Individualisierung der Sepsistherapie zu erreichen!
Publication History
Article published online:
05 December 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Schuster HG, Müller-Werdan U. Definition und Diagnose von Sepsis und Multiorganversagen. In: Schuster HG, Werdan K. Intensivtherapie bei Sepsis und Multiorganversagen. 3. Heidelberg: Springer; 2000: 3-26
- 2 Funk DJ, Parrillo JE, Kumar A. Sepsis and septic shock: a history. Crit Care Clin 2009; 25: 83-101
- 3 Thomas L. Germs. N Engl J Med 1972; 287: 553-555
- 4 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med [Anonym]. 1992; 20: 864-874
- 5 Levy MM, Fink MP, Marshall JC. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256
- 6 Kaukonen KM, Bailey M, Pilcher D. et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 2015; 372: 1629-1638
- 7 Singer M, Deutschman CS, Seymour CW. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801-810
- 8 Ferreira FL, Bota DP, Bross A. et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286: 1754-1758
- 9 Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13: 260-268
- 10 Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003; 3: 169-176
- 11 Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820
- 12 Desaki Y, Miya A, Venkatesh B. et al. Bacterial lipopolysaccharides induce defense responses associated with programmed cell death in rice cells. Plant Cell Physiol 2006; 47: 1530-1540
- 13 Dammermann W, Wollenberg L, Bentzien F. et al. Toll like receptor 2 agonists lipoteichoic acid and peptidoglycan are able to enhance antigen specific IFNγ release in whole blood during recall antigen responses. J Immunol Methods 2013; 396: 107-115
- 14 Zhang Q, Raoof M, Chen Y. et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104-107
- 15 Sagan L. On the origin of mitosing cells. J Theor Biol 1967; 14: 255-274
- 16 Mnich ME, van Dalen R, van Sorge NM. C-type lectin receptors in host defense against bacterial pathogens. Front Cell Infect Microbiol 2020; 10: 309
- 17 Drouin M, Saenz J, Chiffoleau E. C-type lectin-like receptors: head or tail in cell death immunity. Front Immunol 2020; 11: 251
- 18 Bermejo-Jambrina M, Eder J, Helgers LC. et al. C-Type Lectin Receptors in Antiviral Immunity and Viral Escape. Front Immunol 2018; 9: 590
- 19 Park BS, Song DH, Kim HM. et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-1195
- 20 Hayashi F, Smith KD, Ozinsky A. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099-1103
- 21 Broere F, van der Zee R, van Eden W. Heat shock proteins are no DAMPs, rather “DAMPERs”. Nat Rev Immunol 2011; 11: 565
- 22 Yu M, Wang H, Ding A. et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006; 26: 174-179
- 23 Kato H, Takeuchi O, Mikamo-Satoh E. et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008; 205: 1601-1610
- 24 Saito T, Owen DM, Jiang F. et al. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008; 454: 523-527
- 25 Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21: 317-337
- 26 Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707-735
- 27 Vourc’h M, Roquilly A, Asehnoune K. Trauma-induced damage-associated molecular patterns-mediated remote organ injury and immunosuppression in the acutely ill patient. Front Immunol 2018; 9: 1330
- 28 Liu J, Tan Y, Zhang J. et al. C5aR, TNF-α, and FGL2 contribute to coagulation and complement activation in virus-induced fulminant hepatitis. J Hepatol 2015; 62: 354-362
- 29 Stouthard JM, Levi M, Hack CE. et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-742
- 30 Markiewski MM, Nilsson B, Ekdahl KN. et al. Complement and coagulation: strangers or partners in crime?. Trends Immunol 2007; 28: 184-192
- 31 van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8: 32-43
- 32 Prince LR, Allen L, Jones EC. et al. The role of interleukin-1beta in direct and toll-like receptor 4-mediated neutrophil activation and survival. Am J Pathol 2004; 165: 1819-1826
- 33 Kramer F, Torzewski J, Kamenz J. et al. Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaB- and C/EBPbeta-dependent autocrine interleukin-6 loop. Mol Immunol 2008; 45: 2678-2689
- 34 Cahill CM, Rogers JT. Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem 2008; 283: 25900-25912
- 35 Brown GT, Narayanan P, Li W. et al. Lipopolysaccharide stimulates platelets through an IL-1β autocrine loop. J Immunol 2013; 191: 5196-5203
- 36 Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120
- 37 Fielding CA, McLoughlin RM, McLeod L. et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol 2008; 181: 2189-2195
- 38 Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295
- 39 Desai A, Jung MY, Olivera A. et al. IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J Allergy Clin Immunol 2016; 137: 1863-1871.e6
- 40 Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. J Periodontol 1993; 64 (Suppl. 05) 456-460
- 41 Takami M, Terry V, Petruzzelli L. Signaling pathways involved in IL-8-dependent activation of adhesion through Mac-1. J Immunol 2002; 168: 4559-4566
- 42 Heidemann J, Ogawa H, Dwinell MB. et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 2003; 278: 8508-8515
- 43 Weber GF, Chousterman BG, He S. et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 2015; 347: 1260-1265
- 44 Dinarello CA, Novick D, Puren AJ. et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol 1998; 63: 658-664
- 45 Michie HR, Spriggs DR, Manogue KR. et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988; 104: 280-286
- 46 Plata-Salamán CR. 1998 Curt P. Richter Award. Brain mechanisms in cytokine-induced anorexia. Psychoneuroendocrinology 1999; 24: 25-41
- 47 Nieto-Vazquez I, Fernández-Veledo S, Krämer DK. et al. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem 2008; 114: 183-194
- 48 Ming WJ, Bersani L, Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol 1987; 138: 1469-1474
- 49 Morgan BP. The membrane attack complex as an inflammatory trigger. Immunobiology 2016; 221: 747-751
- 50 Gennaro R, Simonic T, Negri A. et al. C5a fragment of bovine complement. Purification, bioassays, amino-acid sequence and other structural studies. Eur J Biochem 1986; 155: 77-86
- 51 Ward PA. The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2010; 2: 439-445
- 52 Simmons J, Pittet JF. The coagulopathy of acute sepsis. Curr Opin Anaesthesiol 2015; 28: 227-236
- 53 Oikonomopoulou K, Ricklin D, Ward PA. et al. Interactions between coagulation and complement – their role in inflammation. Semin Immunopathol 2012; 34: 151-165
- 54 Miyake K. Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res 2006; 12: 195-204
- 55 Aksoy E, Taboubi S, Torres D. et al. The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol 2012; 13: 1045-1054
- 56 Hagar JA, Powell DA, Aachoui Y. et al. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 2013; 341: 1250-1253
- 57 von Moltke J, Ayres JS, Kofoed EM. et al. Recognition of bacteria by inflammasomes. Annu Rev Immunol 2013; 31: 73-106
- 58 Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 2015; 21: 677-687
- 59 Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832
- 60 Liu X, Zhang Z, Ruan J. et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 2016; 535: 153-158
- 61 Wei Y, Kim J, Ernits H. et al. The septic neutrophil – friend or foe. Shock 2021; 55: 147-155
- 62 Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012; 189: 2689-2695
- 63 Berg RE, Forman J. The role of CD8 T cells in innate immunity and in antigen non-specific protection. Curr Opin Immunol 2006; 18: 338-343
- 64 den Haan JM, Bevan MJ. A novel helper role for CD4 T cells. Proc Natl Acad Sci U S A 2000; 97: 12950-12952
- 65 Li Q, Zhang Q, Wang C. et al. Disruption of tight junctions during polymicrobial sepsis in vivo. J Pathol 2009; 218: 210-221
- 66 Duncan DJ, Hopkins PM, Harrison SM. Negative inotropic effects of tumour necrosis factor-alpha and interleukin-1beta are ameliorated by alfentanil in rat ventricular myocytes. Br J Pharmacol 2007; 150: 720-726
- 67 Niederbichler AD, Hoesel LM, Westfall MV. et al. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med 2006; 203: 53-61
- 68 Arnold RC, Dellinger RP, Parrillo JE. et al. Discordance between microcirculatory alterations and arterial pressure in patients with hemodynamic instability. J Crit Care 2012; 27: 531.e1-531.e7
- 69 Filho RR, de Freitas Chaves RC, Assunção MSC. et al. Assessment of the peripheral microcirculation in patients with and without shock: a pilot study on different methods. J Clin Monit Comput 2020; 34: 1167-1176
- 70 van der Poll T, de Boer JD, Levi M. The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis 2011; 24: 273-278
- 71 Schmitt FCF, Manolov V, Morgenstern J. et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care 2019; 9: 19
- 72 Steppan J, Hofer S, Funke B. et al. Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalix. J Surg Res 2011; 165: 136-141
- 73 Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care 2019; 23: 16
- 74 Casserly B, Phillips GS, Schorr C. et al. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med 2015; 43: 567-573
- 75 Otto GP, Sossdorf M, Claus RA. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011; 15: R183
- 76 Wu HP, Wu CL, Chen CK. et al. The interleukin-4 expression in patients with severe sepsis. J Crit Care 2008; 23: 519-524
- 77 Woodward EA, Prêle CM, Nicholson SE. et al. The anti-inflammatory effects of interleukin-4 are not mediated by suppressor of cytokine signalling-1 (SOCS1). Immunology 2010; 131: 118-127
- 78 Sun J, Madan R, Karp CL. et al. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009; 15: 277-284
- 79 O’Garra A, Barrat FJ, Castro AG. et al. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008; 223: 114-131
- 80 Sanjabi S, Zenewicz LA, Kamanaka M. et al. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 2009; 9: 447-453
- 81 Opal SM, Fisher jr. CJ, Dhainaut JF. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-1124
- 82 Ali A, Na M, Svensson MN. et al. IL-1 receptor antagonist treatment aggravates staphylococcal septic arthritis and sepsis in mice. PLoS One 2015; 10: e0131645
- 83 Zhan C, Patskovsky Y, Yan Q. et al. Decoy strategies: the structure of TL1A: DcR3 complex. Structure 2011; 19: 162-171
- 84 Monneret G, Debard AL, Venet F. et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003; 31: 2068-2071
- 85 Cuenca AG, Delano MJ, Kelly-Scumpia KM. et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 2011; 17: 281-292
- 86 Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6: 813-822
- 87 Cui L, Gao Y, Xie Y. et al. An ADAM10 promoter polymorphism is a functional variant in severe sepsis patients and confers susceptibility to the development of sepsis. Crit Care 2015; 19: 73
- 88 Bopp C, Hofer S, Weitz J. et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008; 147: 79-83
- 89 Bopp C, Hofer S, Bouchon A. et al. Soluble TREM-1 is not suitable for distinguishing between systemic inflammatory response syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation. Eur J Anaesthesiol 2009; 26: 504-507
- 90 Ertel W, Kremer JP, Kenney J. et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85: 1341-1347
- 91 Saturnino SF, Prado RO, Cunha-Melo JR. et al. Endotoxin tolerance and cross-tolerance in mast cells involves TLR4, TLR2 and FcεR1 interactions and SOCS expression: perspectives on immunomodulation in infectious and allergic diseases. BMC Infect Dis 2010; 10: 240
- 92 Vergadi E, Vaporidi K, Tsatsanis C. Regulation of endotoxin tolerance and compensatory anti-inflammatory response syndrome by non-coding RNAs. Front Immunol 2018; 9: 2705
- 93 Lin GL, McGinley JP, Drysdale SB. et al. Epidemiology and immune pathogenesis of viral sepsis. Front Immunol 2018; 9: 2147
- 94 Gu X, Zhou F, Wang Y. et al. Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment. Eur Respir Rev 2020; 29: 200038
- 95 Ravindranath TM. Viral sepsis: underrated and underdiagnosed entity in clinical arena. Future Virology 2022; 17: 197-199
- 96 Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M. et al. Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis. Crit Care Med 2021; 49: 2042-2057
- 97 Parthasarathy U, Martinelli R, Vollmann EH. et al. The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders. Biochem Pharmacol 2022; 195: 114847
- 98 Gupta A, Madhavan MV, Sehgal K. et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020; 26: 1017-1032
- 99 Carvelli J, Demaria O, Vély F. et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature 2020; 588: 146-150
- 100 Li J, Liu B. The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy. Cytokine Growth Factor Rev 2021; 58: 75-81
- 101 Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS. et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J 2022; 19: 92
- 102 Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol 2021; 93: 250-256
- 103 Bauer M, Gerlach H, Vogelmann T. et al. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019 – results from a systematic review and meta-analysis. Crit Care 2020; 24: 239
- 104 Seymour CW, Kennedy JN, Wang S. et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 2019; 321: 2003-2017
- 105 Sweeney TE, Azad TD, Donato M. et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med 2018; 46: 915-925